QuantHealth, a Tel Aviv startup, has raised forty five million dollars in Series B funding to grow its clinical trial simulation platform. Qumra Capital led the round, and the company says total funding now stands near seventy million dollars since its 2020 founding.
The pitch is simple to state and hard to achieve: test a trial in software before a single patient is recruited. QuantHealth's tools let drug developers model whether a protocol is likely to succeed, tune who gets included, and estimate commercial outcomes in silico. The company says its predictions are already used inside twelve of the top twenty global pharmaceutical firms.
Why it matters: most candidates that enter human testing fail. The industry's trial failure rate sits around ninety percent, and each miss burns years of work and millions of dollars. A simulation layer that flags weak designs earlier could shrink that waste and push proven drugs to market faster.
The platform draws on large real world datasets and predictive analytics across more than thirty therapeutic areas, including oncology, cardiometabolic disease, and inflammatory conditions. QuantHealth reports up to ninety percent predictive accuracy across more than six hundred simulated trials.
The new capital is earmarked for next generation AI models, broader disease coverage, more scientific validation, and a larger go to market team. Other participants in the round include Pitango HealthTech, Sanofi Ventures, Bertelsmann Healthcare Investments, and several health focused venture funds.
Sources
Techmeme (aggregating Fierce Healthcare): https://www.techmeme.com/260809/p11#a260809p11
MedCity News: https://medcitynews.com/2026/08/quanthealth-ai-drug-discovery
MobiHealth News: https://www.mobihealthnews.com/news/quanthealth-lands-45m-ai-clinical-trial-simulations
HitConsultant: https://hitconsultant.net/2026/08/04/beyond-real-world-trial-iteration-quanthealth-secures-45m-for-ai-clinical-simulation
